- Cardiovascular biomaterials, which include synthetic and natural materials used in the development of implants, stents, grafts, and heart valves, are increasingly becoming essential components in cardiovascular treatments owing to their improved biocompatibility, durability, and ability to restore or support cardiovascular function
- The growing prevalence of cardiovascular diseases (CVDs), rising demand for minimally invasive procedures, and continuous advancements in material sciences are key factors fueling the adoption of cardiovascular biomaterials in both surgical and interventional cardiology applications
- North America dominated the cardiovascular biomaterial market with the largest revenue share of 39.7% in 2024, supported by a robust healthcare infrastructure, early adoption of innovative cardiovascular technologies, and the presence of leading medical device manufacturers. The U.S., in particular, leads the region due to strong R&D investment, favorable reimbursement policies, and a high incidence of heart-related conditions driving biomaterial-based treatment adoption
- Asia-Pacific is expected to be the fastest-growing region in the cardiovascular biomaterial market during the forecast period due to increasing urbanization, rising disposable incomes, growing geriatric population, and greater awareness regarding advanced cardiovascular treatment options in countries such as China, Japan, and India
- The Polymer segment dominated the cardiovascular biomaterial market with the largest revenue share of 38.5% in 2024, attributed to its flexibility, biocompatibility, and wide applicability in cardiovascular devices such as catheters, heart valves, and vascular grafts. Polymer-based materials offer ease of customization and lower immune rejection, driving their adoption
